Regenerex Pharma (RGPX) Cash from Financing Activities (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Cash from Financing Activities data on file, last reported at $397502.0 in Q3 2025.

• Cash from Financing Activities for Q3 2025 came in at $397502.0, up 213.24% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.5 million (up 632.12% YoY), and the FY2025 annual result was $2.3 million, up 392.19% from the prior year.
• Cash from Financing Activities improved to $397502.0 in Q3 2025 per RGPX's latest filing, from -$2652.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.9 million in Q1 2025 and troughed at -$2652.0 in Q2 2025.
• A 5-year average of $182637.9 and a median of $44530.0 in 2022 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 3304.01% in 2025 and fell as far as 104.83% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $20837.0 in 2021, then jumped by 46.85% to $30600.0 in 2022, then surged by 232.04% to $101603.0 in 2023, then jumped by 56.25% to $158757.0 in 2024, then jumped by 150.38% to $397502.0 in 2025.
• Business Quant data shows RGPX's Cash from Financing Activities at $397502.0 in Q3 2025, -$2652.0 in Q2 2025, and $1.9 million in Q1 2025.